Stay updated on ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial page.

Latest updates to the ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded Revision: v3.3.3 and removed HHS Vulnerability Disclosure and Revision: v3.3.2 in the page footer; these are administrative history/version updates and do not affect study data or core content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedNew revision entry v3.3.2 added and v3.2.0 removed from the Record History page (NCT05446298). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check49 days agoChange DetectedRemoved a site-wide notice about funding and NIH operating status from the page. The core trial history content remains unchanged.SummaryDifference0.7%

- Check71 days agoChange DetectedNew history entry dated 2025-07-28 added, updating the study status and oversight details.SummaryDifference0.1%

- Check92 days agoChange DetectedAdded a government funding lapse notice and a v3.2.0 version tag, replacing the prior v3.1.0.SummaryDifference12%

- Check100 days agoChange DetectedThe page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.SummaryDifference0.3%

Stay in the know with updates to ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial page.